Guided Therapeutics (GTHP) Non-Current Deferred Tax Liability (2013 - 2014)
Guided Therapeutics (GTHP) posted Non-Current Deferred Tax Liability of $26.0 million for Q4 2014, up 14.32% sequentially from $22.7 million in Q4 2013, and up 14.32% YoY from $22.7 million in Q4 2013.
Guided Therapeutics (GTHP) Non-Current Deferred Tax Liability (2013 - 2014) Analysis & Trends
Guided Therapeutics has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $26.0 million in Q4 2014.
- Quarterly Non-Current Deferred Tax Liability rose 14.32% year-over-year to $26.0 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $26.0 million (up 14.32% YoY) and the FY2014 annual result came in at $26.0 million, up 14.32% from the prior year.
- Non-Current Deferred Tax Liability grew to $26.0 million in Q4 2014 per GTHP's latest filing, from $22.7 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $26.0 million in Q4 2014 and troughed at $22.7 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 25.99 Mn |
| Dec 31, 2014 | 25.99 Mn |
| Dec 31, 2013 | 22.74 Mn |
| Dec 31, 2013 | 22.74 Mn |